DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5c4591/interstitial_lung) has announced the addition of GlobalData's new report "Interstitial Lung Diseases Global Clinical Trials Review, Q1, 2011" to their offering.
The clinical trial report, Interstitial Lung Diseases Global Clinical Trials Review, Q1, 2011" provides data on the Interstitial Lung Diseases clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Interstitial Lung Diseases. It includes an overview of the trial numbers and their recruitment status as per the site of trial development throughout the world, focusing on the status of participation by the developing nations. It offers coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides information pertaining to the number of trials for the key drugs for treating).
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts.
Scope:
- Data on the number of clinical trials conducted in North America, South And Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status and trial success rate
- Review of key discontinued trials (suspended, withdrawn and terminated)
- Overview of the enrollment pattern by phase for the past decade
- Number of clinical trials segmented by key drugs
- Clinical trial overview of top 20 companies, which include Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, and so on.
- Clinical trial overview of top 20 Universities / Institutes / Hospitals including National Cancer Institute, Cancer Research UK, Cancer Research Institute and others
Reasons to buy:
- Understand the dynamics of a particular indication as a whole
- Examine the performance of the trials in terms of their status, recruitment, success rates and others
- Obtain discontinued trial information for trials across the globe
- Understand the commercial landscape of the major Universities/Institutes/Hospitals or Companies
Key Topics Covered:
1. Table of Contents
2. Introduction 2.1 Interstitial Lung Diseases 2.2 Report Guidance 2.3 Clinical Trials by Region 2.4 Clinical Trials by Country 2.5 Top Countries Contributing to Clinical Trials in Asia-Pacific 2.6 Top Countries Contributing to Clinical Trials in Europe 2.7 Top Countries Contributing to Clinical Trials in North America 2.8 Top Countries Contributing to Clinical Trials in Middle East and Africa
3. Clinical Trials by Phase 3.1 In Progress Trials by Phase
4. Clinical Trials by Trial Status 4.1 Unaccomplished Trials of Interstitial Lung Diseases 4.2 Subjects Recruited Over a Period of Time 4.3 Prominent Sponsors
5. Top Companies Participating in Interstitial Lung Diseases Therapeutics Clinical Trials 5.1 Prominent Drug Comparison 5.2 Clinical Trial Profiles 5.3 Clinical Trial Overview of Top Companies
- Actelion Ltd
- Gilead Sciences, Inc.
- Weill Cornell Medical College
- University of California, San Francisco
- The Alfred Hospital
- Aarhus University
- Katholieke Universiteit
- The University of Chicago
- Columbia University
- University of Michigan
- The Ohio State University
- Maastricht University Medical Center
- University of Pittsburgh
For more information visit http://www.researchandmarkets.com/research/5c4591/interstitial_lung